Kit Patents (Class 435/975)
  • Patent number: 9952215
    Abstract: A method of analyzing an exosome is provided for detecting abnormality in a cell, including: (a) a step of preparing an exosome from a sample; (b) a step of bringing the exosome prepared in the step (a) into contact with a first antibody to a protein which exists on the surface of the exosome as an antigen and forming a first antibody-exosome complex; and (c) a step of measuring a zeta potential of the first antibody-exosome complex.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: April 24, 2018
    Assignees: The University of Tokyo, Nikon Corporation
    Inventors: Takanori Ichiki, Takanori Akagi, Hirofumi Shiono
  • Patent number: 9944706
    Abstract: The technology provided herein relates to novel immunoproteases suitable to induce apotosis in selected diseased target cells, comprising the serine protease granzyme M, and methods for using such cytolytic fusion proteins for the treatment of various diseases, in particular for the treatment of cancer.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: April 17, 2018
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V
    Inventors: Stefan Barth, Sonja Schiffer
  • Patent number: 9676847
    Abstract: The disclosure relates to antibodies against human IL-17 which act as antagonists of IL-17, and their use in the diagnosis or treatment of IL-17 mediated diseases.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 13, 2017
    Assignee: Orega Biotech
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Patent number: 9034657
    Abstract: A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, a
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: May 19, 2015
    Assignee: Phadia AB
    Inventors: Gerd Rundström, Per Matsson, Paul Christopher
  • Patent number: 9028835
    Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. The random copolymers have amino acids alanine, lysine and one or more of the hydrophobic amino acids valine, phenylalanine, tryptophan and tyrosine. Random three-amino acid copolymer FAK efficiently suppressed EAE induced in SJL/J (H-2S) mice with the encephalitogenic epitope PLP 139-151. Random four-amino acid copolymers VYAK and tryptophan-containing VWAK were efficacious in alleviating severity and duration of symptoms of EAE induced by MBP 85-99 (SEQ ID NO:2), in a humanized mouse model expressing genes for both an HLA-DR-2 linked to multiple sclerosis (MS) in humans and for a T cell receptor from an MS patient.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: May 12, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Jack L. Strominger, Masha Fridkis-Hareli
  • Patent number: 9017696
    Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: April 28, 2015
    Assignee: Isis Innovation Limited
    Inventors: Simon Draper, Arturo Reyes, Saranya Sridhar, Adrian Hill, Sarah Gilbert, Anna Goodman
  • Patent number: 9005902
    Abstract: A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: April 14, 2015
    Assignee: Oxford Immunotec Limited
    Inventors: Ajit Lalvani, Ansar Pathan
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Patent number: 8999689
    Abstract: The invention provides novel nucleic acid polymerases from strains GK24 and RQ-1 of Thermus thermophilus, and nucleic acids encoding those polymerases, as well as methods for using the polymerases and nucleic acids.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: April 7, 2015
    Assignee: Applied Biosystems, LLC
    Inventors: James Rozzelle, Elena Bolchakova
  • Patent number: 8992865
    Abstract: The present invention relates to a sealing device for closing an introduction aperture, the sealing device comprising a fixed support and a shutter mounted movably in translation relative to the support between an extended position and a final retracted position, wherein the sealing device is in a final retracted configuration and wherein the shutter closes introduction aperture. The device includes locking means for preventing any movement of the shutter when it is in the final retracted position. The sealing device further comprises an intermediate retracted configuration, wherein the shutter is at least partly retracted. The sealing device also comprises motion guiding means for guiding the movement of the shutter and designed so that the extension of the shutter is required to move the shutter from the intermediate retracted position to the final retracted position.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: March 31, 2015
    Assignee: Biocartis NV
    Inventors: Rob Bosma, Ronald De Gier
  • Patent number: 8975384
    Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 10, 2015
    Assignee: Osaka University
    Inventor: Junichi Takagi
  • Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 8945926
    Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 3, 2015
    Assignee: The Scripps Research Institute
    Inventors: Jason W. Chin, T. Ashton Cropp, J. Christopher Anderson, Peter G. Schultz
  • Patent number: 8926989
    Abstract: The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: January 6, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Burbelo, Adriana Marques, Michael J. Iadarola
  • Patent number: 8927225
    Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: January 6, 2015
    Assignee: The University of Hong Kong
    Inventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
  • Patent number: 8900600
    Abstract: The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: December 2, 2014
    Assignee: VAXON Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Patent number: 8901378
    Abstract: The invention provides DNA compositions that relate to transgenic insect resistant maize plants. Also provided are assays for detecting the presence of the maize TC1507 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: December 2, 2014
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Eric Barbour, James Wayne Bing, Guy A. Cardineau, Robert F. Cressman, Jr., Manju Gupta, Mary E. Hartnett Locke, David Hondred, Joseph W. Keaschall, Michael G. Koziel, Terry EuClaire Meyer, Daniel Moellenbeck, Kenneth Edwin Narva, Wilas Nirunsuksiri, Stephen W. Ritchie, Marjorie L. Rudert, Craig D. Sanders, Aihua Shao, Steven Jeffrey Stelman, David S. Stucker, Laura Ann Tagliani, William M. Van Zante
  • Patent number: 8900824
    Abstract: High affinity antibodies for binding epitopes of BoNT/B and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/B in a sample.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: December 2, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Larry H. Stanker, Miles C. Scotcher, Luisa W. Cheng, Robert M. Hnasko, Jeffery A. McGarvey
  • Patent number: 8900842
    Abstract: The invention relates to a method of storing and/or transporting in vitro two-dimensional cell cultures. The inventive method comprises the following steps consisting in: a) coating a cell culture that is immobilized on an asymmetric support with a gelatine solution in culture medium at a concentration of between 1 and 5%; b) solidifying the gelatine added to the support at a temperature of between 15 and 25° C.; and c) storing and/or transporting the cell culture at a temperature of between 15 and 25° C. for a period of up to 96 hours. The invention also relates to a kit which is used to store and/or transport the in vitro two-dimensional cell cultures according to the inventive method, said kit comprising: i) an asymmetric support, and (ii) a gelatine solution in culture medium at a concentration of between 1 and 5%.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: December 2, 2014
    Assignee: Advanced In Vitro Cell Technologies, S.L.
    Inventors: Myriam Fabre, Sonia Gonzalez Menoyo, Mariana Lopez Matas, Roser Pagan I Esquius
  • Patent number: 8841086
    Abstract: The invention relates to a colorimetric method for detecting bacterial or fungal pathogens by detecting peptidoglycan or (1-3)-?-D-glucan in a sample.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: September 23, 2014
    Assignee: Immunetics, Inc.
    Inventors: Andrew Han, Andrew E. Levin, Neil X. Krueger, Victor Kovalenko
  • Patent number: 8835181
    Abstract: A method for determining the amount of live pore forming bacterial toxin protein in a sample is provided, the method including the steps of a) forming a membrane comprising a lipid bilayer and a receptor, b) contacting the membrane with an ion solution and the sample, c) measuring ion flow through the membrane, d) comparing the ion flow through the membrane to a standard curve, and e) determining the amount of pore forming bacterial toxin protein in the sample. A kit for determining the amount of live pore forming bacterial toxin protein present in the sample is also provided.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 16, 2014
    Inventor: John Cuppoletti
  • Patent number: 8821909
    Abstract: Methods of treating a plant exposed to a phytotoxicant are provided. Embodiments of the subject methods include identifying a plant exposed to a phytotoxicant and applying an assimilable carbon-skeleton energy component-comprising composition to the identified plant. Embodiments of the subject compositions may include one or more of a macronutrient component, micronutrient component, vitamin/cofactor component, complexing agent and microbe. Kits for use in practicing the subject invention are also provided. The subject methods find use in a variety of different applications in which a plant is phytotoxic or at least in danger of becoming phytotoxic due to exposure or potential exposure to a phytotoxicant.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: September 2, 2014
    Inventor: Thomas T. Yamashita
  • Patent number: 8808981
    Abstract: A point-of-care, screening kit for use by a heath care worker to create custom test strips for screening the bodily fluids of an individual for various, medical conditions includes: (a) a plurality of reagents (12), (b) a substrate (18) configured to: i) receive one of the reagents and react with it so as to cause it to acquire a first characteristic color, and, ii) upon the addition of the individual's bodily fluid to the substrate, acquire, as a result of the formulation of each of the reagents, a second, dichotomous characteristic color when the individual has a specific one of the various, medical conditions.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: August 19, 2014
    Assignee: Jhpiego Corporation
    Inventors: Sean Mongale, Shishira Nagesh, Ezra Taylor, Mary O'Grady, Thembi Mdluli, Peter Truskey, Sherri Hall, James Waring, III, Britni Crocker, Harshard Sanghvi, Elaine Yang, Soumyadipta Acharya, Maxim Budyansky, Matthew Means
  • Patent number: 8771710
    Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 8, 2014
    Assignee: Infectious Disease Research Institute
    Inventors: Ajay Bhatia, Steven G. Reed
  • Patent number: 8765145
    Abstract: The present invention pertains to the protection against malaria. More particularly, the invention is based on the characterization of a novel liver and sporozoite-stage P. falciparum antigen, referred to as LSA-5. This antigen is highly antigenic and the prevalence of antibodies in subjects living in endemic areas is extremely high (ca. 90%). The invention concerns antigenic peptides, mixtures thereof, or polypeptides, mixotopes and conjugates comprising part of the sequence of LSA-5, as well as immunogenic compositions, vaccines and kits comprising these.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: July 1, 2014
    Assignee: Vac-4-All Pte. Ltd.
    Inventors: Pierre Druilhe, Karima Brahimi-Zeghidour
  • Patent number: 8759114
    Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 24, 2014
    Assignee: Stichting Voor de Technische Wetenschappen
    Inventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
  • Patent number: 8753863
    Abstract: Disclosed is a method for removing carbon dioxide from the atmosphere. The method comprises the step of delivering urea from a floating vessel to a region of a photic zone of the ocean, whereby the number of phytoplankton is caused to increase in the region upon addition of the urea. The method can be used for producing carbon cells.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: June 17, 2014
    Assignee: Ocean Nourishment Corporation Pty Limited
    Inventors: Ian Stanley Ferguson Jones, William Rodgers, Robert John Wheen, Bruce Joseph Judd
  • Patent number: 8722356
    Abstract: A sampling system and method may use a kit that has a package enclosing a swab and a receptacle. The swab may have a shaft and a tip. The tip may be substantially made of calcium alginate. The receptacle may contain a diluent, such as sodium citrate, and glass beads. The swab may be used in an environment to sample microorganisms present on surfaces or in equipment. The kit may be used in a method of sampling and the resulting sample may be used in a method of quantitative testing.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: May 13, 2014
    Assignee: MicroWorks, Inc.
    Inventor: Dawn E. McIver
  • Patent number: 8715698
    Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: May 6, 2014
    Assignees: Pevion Biotech, AG, Istituto Superiore di Sanita
    Inventors: Rinaldo Zurbriggen, Flavia de Bernardis, Antonio Cassone, Silvia Rasi
  • Patent number: 8716031
    Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 6, 2014
    Assignees: RIKEN, Animal Allergy Clinical Laboratories
    Inventors: Kenichi Masuda, Yasuyuki Ishii, Nobutaka Yasuda
  • Patent number: 8691939
    Abstract: The present invention provides a fluorogenic composition for assaying complement activation that comprises a substrate for C3 convertase that is linked to a first fluorophore and a second fluorophore, wherein the fluorescence of the first and second fluorophores are mutually substantially quenched when the two fluorophores are present at a distance less than the characteristic distance for the two fluorophores. In one embodiment, the fluorescence of the first fluorophore is substantially quenched by the second fluorophore, and the second fluorophore emits heat upon quenching. The present invention also provides a method for assaying complement activation, wherein the method includes the steps of incubating a biological sample with a polymer to provide a polymeric biological sample, followed by incubating the polymeric biological sample with the fluorogenic composition, and measuring the fluorescence.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: April 8, 2014
    Assignee: General Electric Company
    Inventors: Liming Yu, Anup Sood, Mark Felipe Baptista
  • Patent number: 8691953
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Patent number: 8679770
    Abstract: The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: March 25, 2014
    Assignee: Glaxo Smith Kline Biologicals S.A.
    Inventors: Isabel De Vleeschauwer, Nathalie Durant, Jan Poolman, Vincent Weynants
  • Patent number: 8663655
    Abstract: The present invention relates to peptides, nucleic acids and methods for transforming a bacterium belonging to the Streptococcus genus by natural competence and their use in the food and feed industry.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: March 4, 2014
    Assignee: Dupont Nutrition Biosciences APS
    Inventors: Patrick Boyaval, Christophe Fremaux, Pascal Hols, Laetitia Fontaine, Philippe Horvath
  • Patent number: 8637259
    Abstract: The invention relates to the identification of carboxylic acids, present in human sweat, as natural ligands of a specific subgroup of seven olfactory receptor (OR) belonging to class 1 within the OR classification. The invention encompasses the use of the interaction of OR polypeptides and carboxylic acids as the basis of screening assays for agents that specifically modulate the activity of the seven ORs of the invention.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: January 28, 2014
    Assignee: ChemCom S.A.
    Inventors: Pierre Chatelain, Alex Veithen
  • Patent number: 8628933
    Abstract: The invention relates to a kit for a homogenous detection method for the quantitative or qualitative detection of an analyte in an assay and adequate reagents therefor, particularly a homogenous binding test. According to the invention, an analyte-specific binding partner R1 comprises more than one specific binding point for a specific binding partner X that is associated with a component of a signal-forming system while a second analyte-specific binding partner R2 comprises more than one specific binding point for a specific binding partner Y which is also associated with a component of a signal-forming system.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: January 14, 2014
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Carsten Schelp, Michael Trier, Hrair Kirakossian
  • Patent number: 8617885
    Abstract: Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor(IGF), fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of said cells. Methods for identifying expanded hematopoeitc stem cells and kits for ex vivo expansion of hematopoietic stem cells are also provided.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: December 31, 2013
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Chengcheng Zhang, Harvey Lodish
  • Patent number: 8609355
    Abstract: Methods, devices, and kits are provided herein for the accurate and rapid detection of disease causing microbes in a sample by the detection of microbial components of which correlate to the presence of the microbe. Kits include a first binding agent operatively coupled to an immobilized support; and a second binding agent operatively coupled to one or more pH indicating moieties wherein the first and second binding agents bind with sufficient specificity to the microbial component to permit detection of that component which correlates to the presence of the microbe in the sample.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: December 17, 2013
    Assignee: Indicator Systems International, Inc.
    Inventors: Gerald F. Swiss, Laurie B. F. Stellman
  • Patent number: 8609436
    Abstract: The invention provides a method of detecting the presence of anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and detecting the binding or absence of binding of antibodies to said recombinant MHC molecules. This method allows the detection and/or identification of one or more specific MHC particularly HLA allele antibodies.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: December 17, 2013
    Assignees: Guy's & St Thomas' Hospital NHS Trust (“GST”), King's College London, Oxford Radcliffe Hospital NHS (“ORH”) Trust of the John Radcliffe Hospital
    Inventors: Martin C. N. M. Barnardo, Andrea W. Harmer, Michael Bunce, Robert W. Vaughn, Kenneth I. Welsh
  • Patent number: 8609819
    Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 17, 2013
    Assignee: Board of Trutees of the University of Arkansas
    Inventors: Timothy J O'Brien, Lowell J Underwood, John Beard, Kazushi Shigemasa
  • Patent number: 8591904
    Abstract: A conjugate of a modified randomly branched asymmetric polymer without a core and a member of a binding pair is described. The modified randomly branched asymmetric polymer can contain chain branches, terminal branches or both. The modified randomly branched asymmetric polymer can contain random asymmetric branches or random asymmetric junctions. The binding pair can be an antibody, antigen or a ligand. The conjugate includes a drug.
    Type: Grant
    Filed: July 11, 2010
    Date of Patent: November 26, 2013
    Assignee: ANP Technologies, Inc.
    Inventors: Ray Yin, Dujie Qin, Jing Pan
  • Patent number: 8591899
    Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 26, 2013
    Assignee: State of Israel, Represented by Prime Minister's Office, Israel Institute for Biological Research
    Inventors: Avigdor Shafferman, Ofer Cohen, Theodor Chitlaru, Sagit Sela-Abramovich, Orit Gat
  • Patent number: 8568716
    Abstract: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: October 29, 2013
    Assignee: Proteon Therapeutics, Inc.
    Inventor: F. Nicholas Franano
  • Patent number: 8568989
    Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: October 29, 2013
    Assignee: Abaxis, Inc.
    Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
  • Patent number: 8569470
    Abstract: The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: October 29, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Diógenes Quintana Vázquez, Tamara Menendez Medina, Anabel Álvarez Acosta, Yoelys Cruz Leal, Gerardo Enrique Guillen Nieto
  • Patent number: 8563327
    Abstract: The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 22, 2013
    Assignees: Seoul National University Hospital, SNU R&DB Foundation
    Inventors: Sang Gyu Park, Kyong Soo Park, Sunghoon Kim
  • Patent number: 8563329
    Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: October 22, 2013
    Assignee: ANP Technologies, Inc.
    Inventors: Ray Yin, Dujie Qin, Jing Pan
  • Patent number: 8546100
    Abstract: A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration agent that comprises diatomaceous earth bearing, on at least a portion of its surface, a surface treatment comprising a surface modifier comprising titanium dioxide, fine-nanoscale gold or platinum, or a combination thereof; (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: October 1, 2013
    Assignee: 3M Innovative Properties Company
    Inventors: Manjiri T. Kshirsagar, Tushar A. Kshirsagar, Thomas E. Wood
  • Patent number: 8518653
    Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: August 27, 2013
    Assignee: Teknologian Tutkimuskeskus VTT
    Inventors: Kristiina Takkinen, Hans Söderlund, Timo Pulli
  • Patent number: 8507260
    Abstract: Disclosed is a lateral flow capillary device and uses thereof comprising a unipath bibulous capillary flow matrix and at least two reservoirs each in fluid communication with the capillary flow matrix wherein a reservoir contacts the capillary flow matrix through a passage having a rim pressing the matrix. The pressure that the rim applies on the matrix prevents leakage of liquids out of the capillary flow matrix at the reservoir/ matrix interface, allowing accurate sequential draining of liquid from the reservoirs.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: August 13, 2013
    Assignee: Realbio Technologies, Ltd.
    Inventors: Sara Alajem, Avraham Reinhartz